** Drugmaker Ionis Pharmaceuticals' IONS.O shares rise 4.5% to $33.40 premarket
** IONS posts Q4 sales of $227 mln, above analysts' est of $137.6 mln - LSEG
** Co reports Q4 loss of 66 cents/share vs analysts' est loss of $1.12/share - LSEG
** Co expects 2025 rev to be over $600 mln; analysts on avg expect 2025 rev to be $676 mln - LSEG
** As of December 31, 2024, IONS had cash, cash equivalents and short-term investments of $2.3 bln
** Co forecasts cash, cash equivalents and short-term investments of about $1.7 bln for 2025
** IONS fell ~34% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.